Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SLC40A1 | Q9NP59 | 11/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 2/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4129852 | 0.89 | HIF1A (0.38) | NPC1RAB9ASMN1; SMN2SLC40A1 | |
| SCHEMBL4135557 | 0.88 | SLC40A1 (0.36) | SLC40A1DHODH | |
| SCHEMBL4123415 | 0.88 | MAPK14 (0.34) | SLC40A1KDM4EMAPK1DHODHROCK2 | |
| SCHEMBL4118238 | 0.86 | POLB (0.39) | SLC40A1KDM4EDHODHROCK2 | |
| SCHEMBL4138886 | 0.83 | DHODH (0.32) | KDM4EMAPK1DHODHROCK2 | |
| SCHEMBL3652325 | 0.83 | NPC1 (0.34) | NPC1RAB9ASMN1; SMN2KDM4EMAPK1 | |
| SCHEMBL4130943 | 0.82 | MAPT (0.38) | MAPK1ROCK2 | |
| SCHEMBL4137742 | 0.80 | GSK3B (0.38) | DHODH | |
| SCHEMBL4125989 | 0.80 | GAA (0.36) | NPC1RAB9ASMN1; SMN2KDM4EMAPK1 | |
| SCHEMBL4118036 | 0.77 | DHODH (0.36) | NPC1RAB9ASLC40A1DHODHROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | NPC1 53/4885RAB9A 167/4885SMN1; SMN2 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.